Bayer AG (BYR.L) on Thursday said the U.S. Food and Drug Administration has granted priority review to its supplemental New Drug Application for Kerendia as a treatment for adults with Type 1 Diabetes and Chronic Kidney Disease.
The application is supported by data from the Phase III FINE-ONE trial, which showed Kerendia significantly reduced urine albumin-to-creatinine ratio over six months compared with placebo when added to standard of care in adults with Type 1 diabetes and chronic kidney disease. Bayer also included pooled Phase III data from the FIDELIO-DKD and FIGARO-DKD trials involving patients with chronic kidney disease associated with Type 2 Diabetes.
Kerendia is already approved for chronic kidney disease associated with Type 2 diabetes and for certain patients with heart failure.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.